Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01145885
Recruitment Status : Completed
First Posted : June 17, 2010
Results First Posted : January 31, 2019
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of safety, tolerability and preliminary therapeutic effects of [14C]volasertib in patients with advanced solid tumours.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BI 6727 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug
Study Start Date : June 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Arm Intervention/treatment
Experimental: BI 6727
BI 6727 cycles in every 21 days
Drug: BI 6727
PLK-1 inhibitor




Primary Outcome Measures :
  1. Individual Time Course Profiles of 14C-radioactivity in Whole Blood and Plasma: Cmax of 14C Labelled Volasertib [ Time Frame: Whole blood: Pre-dose (-0.5 hours (h)) and 1.0h, 1.983h, 4h, 6h, 8h and 24h after start of the 2h drug infusion.Plasma: Pre-dose (-0.5h) and 1.0h, 1.983h, 4h, 6h, 8h, 24h,48h. 96h, 168h and 336h after start of drug infusion. ]
    Individual time course profiles of 14C-radioactivity in whole blood and plasma: Cmax of 14C labelled Volasertib.

  2. Individual Time Course Profiles of 14C-radioactivity in Urine: Cumulative Fraction of 14C-ratioactivity Excreted in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Percentage of administered dose excreted in urine as 14C-radioactivity over time

  3. Individual Time Course Profiles of 14C-radioactivity in Faeces: Cumulative Fraction of 14C-radioactivity Excreted in Faeces [ Time Frame: Every 24 hours, up to 504 hours ]
    Percentage of administered dose excreted in faeces as 14C-radioactivity over time

  4. Individual Time Course Profiles of Volasertib and CD 10899 in Plasma: Cmax of Volasertib and CD 10899 (a Metabolite of Volasertib). [ Time Frame: Plasma: Pre-dose (-0.5h) and 1.0h, 1.983h, 4h, 6h, 8h, 24h,48h. 96h, 168h and 336h after start of drug infusion. ]
    Individual time course profiles of volasertib (BI 6727) and a metabolite of volasertib (CD 10899), in plasma: Cmax of Volasertib and CD 10899.

  5. Individual Time Course Profile of Volasertib in Urine:Cumulative Fraction of Volasertib Excreted in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Percentage of administered dose excreted in urine as volasertib (BI 6727) over time

  6. Individual Time Course Profile of CD 10899 in Urine: Cumulative Amount of CD 10899 Excreted in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Cumulative amounts of CD 10899, a metabolite of volasertib, excreted in urine over time

  7. Rate and Extent of Excretion Mass Balance Based on the Total Radioactivity in Urine and Faeces: Cumulative Fraction of Excretion 504 Hours After Start of Drug Infusion. [ Time Frame: up to 504 hours ]
    Cumulative Percentage of 14C-radioactivity excreted in urine and faeces at 504 hours after start of drug infusion related to total [14C] volasertib administered.

  8. Cmax of Volasertib and CD 10899 in Plasma [ Time Frame: 30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion ]
    Maximum measured concentration of volasertib and CD 10899, a metabolite of volasertib, in plasma (Cmax).

  9. AUC0-inf of Volasertib and CD10899 in Plasma [ Time Frame: 30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion ]
    Area under the concentration-time curve of volasertib and CD 10899, a metabolite of volasertib, in plasma over the time interval from 0 to infinity (AUC0-inf).

  10. CL/R of Volasertib and CD 10899 in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Renal clearance of the analyte in urine (CL/R) within the time interval 0 hours to 504 hours of volasertib and CD 10899, a metabolite of volasertib.

  11. Ae(0-tz) of Volasertib and CD 10899 in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Amount of analyte eliminated in urine within the time interval 0 hours to last quantifiable data point (Ae(0-tz)) for volasertib and CD 10899, a metabolite of volasertib.

  12. AUC0-tz of 14C Radioactivity in Plasma and Whole Blood [ Time Frame: 30 minutes (min) before start of infusion and 1 hour (h), 1h 59min, 4h, 6h, 8h, 24h, 48h, 96h, 168h and 336h after start of infusion for plasma; 30 min before start of infusion and 1h, 1h 59min, 4h, 6h, 8h and 24h after start of infusion for whole blood ]
    Area under the concentration-time curve of 14C radioactivity in plasma and whole blood over the time interval from 0 to the last quantifiable data point (AUC0-tz).

  13. Ae(0-tz) of 14C Radioactivity in Urine [ Time Frame: Every 24 hours, up to 504 hours ]
    Amount of analyte eliminated in urine within the time interval 0 to to the last quantifiable data point (Ae(0-tz)) of 14C radioactivity

  14. Ae,Faeces(0-tz) of 14C Radioactivity [ Time Frame: Every 24 hours, up to 504 hours ]
    Amount of analyte excreted in faeces within the time interval 0 to to the last quantifiable data point (Ae(0-tz)) of 14C radioactivity

  15. Time Dependency of Cblood Cells/Cplasma Ratio and Cblood/Cplasma Ratio of 14C-radioactivity [ Time Frame: 1.983 hours and 6 hours ]
    Time dependency of Cblood cells/Cplasma ratio and Cblood/Cplasma ratio of 14C-radioactivity.

  16. Elucidation of Metabolite Structures and Identification of Major Metabolites in Plasma, Urine, and Faeces [ Time Frame: 3 weeks ]

    Elucidation of mb structures and identification of major metabolites in plasma, urine, and faeces. This endpoint was not analysed in the study report.

    The contribution of volasertib and the metabolite CD 10899 to total radioactivity in plasma in the time interval 0 to 8 h after drug administration supports the suggestion that other metabolites in addition to CD 10899 are present in plasma. However, different methods used for the quantification of volasertib and CD 10899 (HPLC MS/MS) and total 14C-radioactivity (liquid scintillation counting) have to be taken into account for the interpretation of the difference between total 14C-radioactivity and analysis of volasertib and CD 10899 in plasma and the plasma metabolite pattern remains to be categorized.



Secondary Outcome Measures :
  1. Percentage of Participants With Drug Related Adverse Events [ Time Frame: From first intake of study drug until 21 days after last intake of the study drug, up to 63 days ]
    Percentage of participants with drug related adverse events (AEs)

  2. Percentage of Participants With Clinically Relevant Abnormalities for Clinical Assessments, ECG, Vital Signs and Laboratory Tests [ Time Frame: From first intake of study drug until 21 days after last intake of the study drug, up to 63 days ]
    Percentage of participants with clinically relevant abnormalities for clinical assessments, electrocardiogram (ECG), vital signs and clinical laboratory test parameters. New abnormal findings or worsening of baseline conditions were reported as adverse events.

  3. Percentage of Participants With Clinical Benefit [ Time Frame: 21, 42 and 63 days ]
    The endpoint tumour response was was analysed as the percentage of participants with clinical benefit after each treatment cycle based on the Investigator's response assessment (with clinical assessment being conducted after every cycle and radiological assessment at the Investigator's discretion).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Inclusion Criteria 1. Patients with histologically or cytologically confirmed diagnosis of advanced, non resectable and / or metastatic solid tumour
  • Inclusion Criteria 2. Male
  • Inclusion Criteria 3. Age >=18 and =<70 years
  • Inclusion Criteria 4. Written informed consent
  • Inclusion Criteria 5. Eastern Cooperative Oncology Group (ECOG) performance score =<2
  • Inclusion Criteria 6. Recovery from Common Terminology Criteria for Adverse Events (CTCAE) Grade >=2 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy

Exclusion criteria:

  • Exclusion Criteria 1. Serious concomitant non-oncological disease considered by the investigator
  • Exclusion Criteria 2. Active infectious disease
  • Exclusion Criteria 3. Viral hepatitis, Human Immunodeficiency Virus (HIV) infection
  • Exclusion Criteria 4. Clinical evidence of active brain metastasis during the past 6 months
  • Exclusion Criteria 5. Second malignancy currently requiring active therapy
  • Exclusion Criteria 6. Absolute neutrophil count less than 1,500/mm3
  • Exclusion Criteria 7. Platelet count less than 100,000/mm3
  • Exclusion Criteria 8. Total bilirubin greater than 1.5 mg/dL
  • Exclusion Criteria 9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
  • Exclusion Criteria 10. Serum creatinine greater than 1.5x Upper Limit of Normal (ULN).
  • Exclusion Criteria 11. Known history of QT/QTcF-prolongation
  • Exclusion Criteria 12. Patients who are sexually active and having a partner with childbearing potential and unwilling to use a medically acceptable method of contraception
  • Exclusion Criteria 13. Treatment with other investigational drugs or participation in another clinical trial
  • Exclusion Criteria 14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy within the past four weeks prior to start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.
  • Exclusion Criteria 15. Alcohol abuse
  • Exclusion Criteria 16. Life expectancy less than 12 weeks
  • Exclusion Criteria 17. Potent Cytochrome P450 enzyme (CYP) 3A4 and P-glycoprotein inhibitors or inducers
  • Exclusion Criteria 18. History of allergy/hypersensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01145885


Locations
Layout table for location information
Hungary
1230.23.36001 Boehringer Ingelheim Investigational Site
Budapest, Hungary
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01145885    
Other Study ID Numbers: 1230.23
2009-018199-32 ( EudraCT Number: EudraCT )
First Posted: June 17, 2010    Key Record Dates
Results First Posted: January 31, 2019
Last Update Posted: January 31, 2019
Last Verified: August 2018